| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | kgp |
| Uniprot No | B2RLK2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 229-594aa |
| 氨基酸序列 | DVYTDHGDLYNTPVRMLVVAGAKFKEALKPWLTWKAQKGFYLDVHYTDEAEVGTTNASIKAFIHKKYNDGLAASAAPVFLALVGDTDVISGEKGKKTKKVTDLYYSAVDGDYFPEMYTFRMSASSPEELTNIIDKVLMYEKATMPDKSYLEKALLIAGADSYWNPKIGQQTIKYAVQYYYNQDHGYTDVYSYPKAPYTGCYSHLNTGVGFANYTAHGSETSWADPSLTATQVKALTNKDKYFLAIGNCCVTAQFDYPQPCFGEVMTRVKEKGAYAYIGSSPNSYWGEDYYWSVGANAVFGVQPTFEGTSMGSYDATFLEDSYNTVNSIMWAGNLAATHAGNIGNITHIGAHYYWEAYHVLGDGSVM |
| 预测分子量 | 48.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Kgp(牙龈卟啉单胞菌赖氨酸特异性牙龈蛋白酶)重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**: *Structural and functional characterization of recombinant Lys-gingipain from Porphyromonas gingivalis*
**作者**: Olsen I, Potempa J, et al.
**摘要**: 本研究通过重组表达系统成功纯化Kgp蛋白酶，解析其晶体结构并揭示其底物结合机制。发现Kgp通过特异性切割赖氨酸残基破坏宿主免疫蛋白(如补体成分)，促进牙周炎发展。
---
2. **文献名称**: *Recombinant Kgp domain as a potential vaccine target against periodontal disease*
**作者**: DeCarlo AA, et al.
**摘要**: 构建重组Kgp蛋白的免疫原性片段，动物实验表明其可诱导中和抗体，抑制牙龈卟啉单胞菌的黏附与定植，为牙周病疫苗开发提供理论依据。
---
3. **文献名称**: *Expression optimization and enzymatic properties of recombinant Kgp in Escherichia coli*
**作者**: Chen X, et al.
**摘要**: 通过密码子优化和表达条件筛选，在大肠杆菌中实现Kgp的高效可溶性表达。酶活分析显示重组蛋白具有与天然酶相似的pH依赖性和抑制剂敏感性，为大规模制备奠定基础。
---
**备注**：上述文献为示例性质，实际研究中建议通过PubMed或Web of Science以关键词“Kgp gingipain recombinant”检索最新论文，并优先选择高被引或权威期刊文献(如*Journal of Biological Chemistry*或*Molecular Oral Microbiology*)。
**Background of KGP Recombinant Protein**
KGP recombinant protein is a genetically engineered antigen designed for vaccine development, particularly in the context of infectious diseases. The term "KGP" likely refers to a modified version of a viral structural protein—commonly the spike (S) protein of SARS-CoV-2—optimized for stability, immunogenicity, and scalable production. Such recombinant proteins are produced by inserting the target gene into host systems (e.g., insect or mammalian cells) to express and purify the antigen.
In COVID-19 vaccine research, similar recombinant proteins, like Novavax’s NVX-CoV2373. utilize a stabilized S protein with proline substitutions ("S-2P") to maintain prefusion conformation, enhancing neutralizing antibody responses. KGP may incorporate analogous modifications, such as furin cleavage site removal or disulfide bond stabilization, to improve antigenic fidelity and safety. These design choices aim to mimic the virus’s natural structure, enabling robust B-cell and T-cell immune activation.
Recombinant protein platforms are favored for their safety profile compared to live-virus vaccines, scalability, and compatibility with adjuvants (e.g., Matrix-M) to boost efficacy. KGP-based candidates may target emerging variants through rapid gene sequence updates, aligning with pandemic preparedness goals. Preclinical and clinical studies typically assess immunogenicity, protective efficacy in animal models, and thermostability—an advantage for global distribution.
Overall, KGP represents a versatile tool in subunit vaccine development, balancing innovation in protein engineering with practical manufacturing demands. Its design principles and applications reflect broader trends in leveraging recombinant technology against evolving pathogens.
×
